TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Georgetown University
Updated on 9 February 2022
measurable disease
advanced breast cancer


This is a multi-institutional pilot trial for patients with advanced breast cancer. The trial is designed to assess the safety and tolerability of induction talazoparib followed by combination of talazoparib and avelumab. As an exploratory endpoint, the study team will evaluate the immunomodulatory effects of induction talazoparib followed by the combination of talazoparib and avelumab in patients with advanced breast cancer.

Condition Breast Cancer
Treatment Avelumab, Talazoparib
Clinical Study IdentifierNCT03964532
SponsorGeorgetown University
Last Modified on9 February 2022


Yes No Not Sure

Inclusion Criteria

Histologically confirmed advanced breast cancer not amenable to curative treatment by surgery or radiotherapy, that is amenable to biopsy
Radiographically measurable disease by RECIST v1.1
Age 18 years
Life expectancy of more than 3 months
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Signed informed consent form
Patients with a standard 12-lead electrocardiogram (ECG) with the following parameters at screening (defined as the mean of the triplicate ECGs)
QTc interval at screening < 481 msec
Resting heart rate 50-100bpm
Adequate hepatic, bone marrow, and renal function at the time of enrollment
Bone Marrow: Absolute neutrophil count (ANC) 1,500/mm3; Platelets 100,000/mm3; Hemoglobin 9.0 g/dL. Patients must be able to meet the criteria without transfusion or receipt of colony stimulating factors within 2 weeks before obtaining sample
Creatinine clearance 60 mL/min based on Cockcroft-Gault equation
Hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 the upper normal limit of institution's normal range. Total bilirubin 1.5 the upper normal limit of institution's normal range. For subjects with liver metastases, AST and ALT < 5 the upper normal limit of institution's normal range, and total bilirubin >1.5 - 3.0 x the upper normal limit of institution's normal range are acceptable as long as there is no persistent nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, or eosinophilia
Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) must be 2 X the upper limit of the institution's normal range and International Normalized Ratio (INR) < 2\. Subjects on anticoagulation (such as coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigator
Patients may have received an unlimited number of prior therapies. The last dose of systemic therapy must have occurred a minimum of 2 weeks prior to C1D1
Patients must have fully recovered from all effects of surgery. Patients must have had at least two weeks after minor surgery and four weeks after major surgery before starting therapy. Minor procedures requiring conscious sedation such as endoscopies or mediport placement may only require a 24-hour waiting period, but this must be discussed with an investigator
Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and/or postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
Patient is capable of swallowing pills whole
Subject, or legally authorized representative (LAR) is capable of understanding and complying with parameters as outlined in the protocol and able to sign and date the informed consent, approved by the IRB, prior to the initiation of any screening or study-specific procedures
Patient, or LAR, must consent to multiple biopsies during study

Exclusion Criteria

Prior exposure to PARP inhibitor-based therapy
Prior disease progression while receiving anti-PD-1 or anti-PD-L1 therapy within 6 months of use
Recent severe infection or antibiotic use, or known chronic infection with human immunodeficiency virus (HIV) or hepatitis B virus
Diagnosis of immunodeficiency or is receiving systemic steroid or other immunosuppressive therapy
Active autoimmune disease that has required systemic treatment in the past 2 years
History of tuberculosis
History of allogenic bone marrow transplant or solid organ transplant
Live vaccine administration within 30 days of planned start of study therapy
Cardiovascular disease problems including unstable angina, therapy for lifethreatening ventricular arrhythmia, or myocardial infarction, stroke within the last 6 months, or a diagnosis of congestive heart failure
Women who are pregnant or breastfeeding
Patients with known untreated central nervous system (CNS) metastases
Patients with history of another active malignancy within the past 2 years, excluding non-melanoma carcinoma of the skin
Patients receiving any other investigational agents
Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1
History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest CT scan
Life-threatening visceral disease or other severe concurrent disease that would, in the investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study or compromise compliance with the protocol
Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs
Presence of a psychiatric illness or social situation that would limit compliance with study requirements
Patients must not have had radiotherapy encompassing >20% of the bone marrow
Patients must not have current evidence of any condition, therapy, or laboratory abnormality (including active or uncontrolled myelosuppression [ie, anemia, leukopenia, neutropenia, thrombocytopenia]) that might confound the results of the study or interfere with the patient's participation for the full duration of the study treatment or that makes it not in the best interest of the patient to participate
Patients must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
Current use of potent P-gp inhibitors within 7 days prior to randomization. For a list of potent P-gp inhibitors
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note